+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.

Age: 18Years +All GendersPhase 3
195 locations
P

Actively Recruiting

Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.

Age: 18Years +MALEPhase 3
231 locations
E

Actively Recruiting

Researchers are evaluating whether adding the drug pirtobrutinib to the usual R-CHOP chemotherapy regimen improves treatment outcomes for people with Richter transformation, a condition where chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a faster-growing large B-cell lymphoma. This phase III trial aims to assess safety and effectiveness of this combination compared to R-CHOP alone, with additional goals to investigate genetic mutations associated with the disease and patient-reported symptoms. Participants are randomly assigned to one of two groups. One group receives pirtobrutinib orally daily on days 1 to 21 of each 21-day cycle along with the R-CHOP drugs given intravenously or subcutaneously during 6 cycles, followed by continued pirtobrutinib for up to 5 years if the disease does not progress. The other group receives only the standard R-CHOP treatment for 6 cycles. Pirtobrutinib and R-CHOP drugs include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Some patients may receive an additional treatment cycle if needed. Participants undergo various assessments including heart function tests echocardiography or MUGA scan and imaging scans CT or PETCT throughout the study. Blood and tissue samples are collected for genetic and disease monitoring. Researchers measure progression-free survival, overall survival, response rates, adverse events, and patient-reported symptoms. Follow-up continues for up to 7 years after treatment to monitor long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
62 locations
M

Actively Recruiting

Researchers are investigating the safety and effectiveness of cenegermin eye drops to heal persistent corneal epithelial defects PCED, a condition where the cornea does not properly heal. This phase 3 clinical trial compares cenegermin with a placebo vehicle to see how well it induces complete healing after 4 weeks of treatment. The study is conducted across multiple centers with participants randomly assigned to groups, and both participants and researchers do not know who receives which treatment. Participants will receive either cenegermin or a placebo eye drop applied topically to the affected eye. The study includes three periods an initial 8-week treatment phase, followed by an 8-week extension treatment phase for continued evaluation, and finally a 24-week follow-up phase to monitor long-term outcomes. Participants are randomly assigned to one of the two groups, and the treatment is administered throughout these periods. During the study, participants will be regularly assessed to monitor corneal healing and safety. Measurements include the proportion of participants achieving complete healing at 4 and 8 weeks, changes in the size of the corneal defect, and monitoring of any adverse events up to week 40. Study visits and evaluations will track progress and safety over the total study duration, ensuring careful follow-up of all participants.

Age: 18Years +All GendersPhase 3
77 locations
P

Actively Recruiting

Neurotrophic keratopathy NK is a degenerative eye disease caused by damage to the nerves that supply the cornea, leading to reduced sensitivity and impaired healing of the corneal surface. Researchers are evaluating the safety and effectiveness of a new eye drop solution called 0.1% RGN-259 compared to a placebo for treating this condition. This Phase 3, randomized, multi-center clinical study aims to better understand how well RGN-259 helps heal the cornea in people with NK. Participants will be randomly assigned to receive either the RGN-259 eye drops or a placebo solution. Both treatments are preservative-free, sterile eye drops applied directly into the affected eyes five times daily for 28 days. The RGN-259 contains thymosin beta 4 T4, which is being studied for its potential healing properties, while the placebo has the same ingredients except for T4. The study is double-masked to ensure unbiased results. During the study, participants will have regular assessments including eye examinations, measurements of corneal healing, visual acuity tests, and corneal sensitivity checks using specialized tools. The main outcome measured is the percentage of subjects who achieve complete healing of the persistent epithelial defect by Day 29. Follow-up visits will continue up to Day 43 to monitor changes in lesion size and corneal health. Safety will also be closely monitored throughout the trial, which is expected to end in May 2026.

Age: 18Years +All GendersPhase 3
36 locations
A

Actively Recruiting

Researchers are evaluating the feasibility and usefulness of creating predictive models to determine how patients with depressed mood might respond to different treatments. This study focuses on using real-world clinical data to support personalized treatment decisions for depression. It will include patients treated with esketamine, conventional transcranial magnetic stimulation TMS, or Stanford Accelerated Intelligent Neuromodulation Therapy SAINT. Existing clinical and research data may also be used to help develop and validate these models. Participants will be grouped based on the treatment they receive as part of their usual care esketamine, conventional repetitive TMS, or SAINT. The study will observe these treatments without altering standard care. Retrospective data may be included to enhance the studys findings. This observational study does not involve assigning treatments but monitors outcomes under normal clinical conditions. During the study, participants will complete the Patient Health Questionnaire 9-item PHQ-9 before treatment, immediately after treatment, two weeks post-treatment, and monthly for up to 12 months. Researchers will collect and analyze clinical data to develop tools that could help predict treatment response. The study runs until March 2037, allowing long-term follow-up and evaluation of treatment outcomes over time.

Age: 18Years +All Genders
2 locations
E

Actively Recruiting

Researchers are evaluating the safety and performance of the LivIQ leadless pacemaker system in patients who require ventricular pacing for conditions like bradycardia, AV block, or other cardiac rhythm disorders. This study is an open-label, prospective, single-arm international trial enrolling 325 subjects across multiple centers in the U.S., Europe, and Asia Pacific. It includes a specific sub-study designed to assess how well the device maintains atrioventricular synchrony AVS. Participants will receive the LivIQ leadless pacemaker, which is implanted directly into the right ventricle. The study includes scheduled visits at enrollment, device implant, pre-hospital discharge, and follow-ups at 1, 3, 6, and 12 months, continuing every 6 months until regional market approval. After U.S. approval, a remote visit at 24 months will check vital status. The AVS sub-study involves additional Holter monitoring at 1 and 6 months to evaluate device performance. Participants will undergo evaluations including physical examinations, device performance assessments, and quality of life questionnaires. Researchers will monitor serious adverse device effects, pacing and sensing adequacy, battery longevity, and survival rates over time. Follow-up includes in-person visits and remote monitoring to track safety and device function, with participation lasting up to about two years or more depending on market approvals.

Age: 18Years +All GendersPhase Not Applicable
43 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness of Selective Laser Trabeculoplasty SLT at low energy compared to standard energy for treating glaucoma and ocular hypertension. The study also aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications than waiting to repeat standard energy SLT until its effects wear off. This is a Phase 3 randomized trial focusing on treatment optimization for these eye conditions. Participants initially receive SLT treatment at standard energy, where energy levels are adjusted to produce champagne bubbles as a sign of effectiveness. At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually with low energy or as needed with standard energy. The low energy SLT involves 100 treatment spots delivered at a lower energy level, adjusted as needed to maintain optimal response, while the standard energy SLT uses higher energy levels with similar adjustments. One arm of the initial low energy SLT was discontinued after interim analysis. Throughout the study, participants undergo regular eye pressure measurements and monitoring up to 48 months. Researchers measure outcomes such as survival without needing additional treatment at 12 and 48 months, average intraocular pressure IOP over time, and incidence of IOP spikes. Participants will attend scheduled visits for assessments and treatment as needed, with the total study duration lasting several years to evaluate long-term effects and safety.

Age: 18Years +All GendersPhase 3
29 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
E

Actively Recruiting

Lung cancer is the leading cause of cancer-related death in the United States, and annual lung cancer screening with low-dose computed tomography LDCT has been shown to reduce mortality. However, many people who are eligible for screening based on U.S. Preventive Services Task Force guidelines do not undergo it. This study evaluates new strategies to improve lung cancer screening uptake among adults aged 50 to 80 with a significant smoking history. Participants will be randomly assigned to either enhanced usual care, which includes an educational brochure, or an intervention called Empower LCSCall. The Empower LCS intervention features patient education, provider notifications, patient reminders, and information about financial and community resources. Those who do not complete screening after the initial intervention may receive additional telephone navigation through the Call program to address barriers and assist with scheduling. Participants complete baseline and follow-up surveys at 4 and 8 months. Researchers will review electronic health records to assess discussions, orders, and completion of lung cancer screening. Some participants will also be invited to a one-time interview about their experiences. The study aims to assess the feasibility, acceptability, and preliminary effectiveness of the intervention to inform future efforts to improve equitable access to lung cancer screening.

Age: 50Years - 80YearsAll GendersPhase Not Applicable
57 locations

1-10 of 26

1